MAP2 and depressive symptom measurement: PKA, a binding partner and kinase of MAP2, acts downstream of voltage-gated calcium channels (Davare et al., 1999), which are now clearly identified by unbiased genomic studies as contributing to risk in schizophrenia, bipolar disorder, depression, and autism spectrum disorders (Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011; Lu et al., 2012; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Rao et al., 2016).